🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Androgen receptor activation for breast cancer therapy Considering the role of AR in normal breast biology, this might have been the wrong approach. Instead of blocking AR, does it need to be activated? nature.com/articles/s4156…

Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance 💥Excellent review👇 esmoopen.com/article/S2059-…

Nonoperative Management of Mismatch Repair–Deficient Tumors Stage 1-3, 6-mo dostarlimab cCR All ➡️ 84 pts (82%) Rectal➡️💯% Other➡️65% Almost all patients with CCR did not undergo surgery 2y RFS➡️92% 💥ctDNA correlated with response #AACR25 nejm.org/doi/full/10.10…

Association of Gene Variant Type and Location with Breast Cancer Risk in the General Population 📌PTVs in BRCA2 exon 11 are associated with lower BC risk, older age at diagnosis, and higher risk of ER-negative disease compared to other exons 💥Variant location may inform

Zongertinib in Previously Treated HER2-Mutant NSCLC Zongertinib: oral, irreversible, HER2-selective TKI TK domain mutations➡️ORR: 71%, PFS: 12.4 mo Non-TK domain mutations➡️ ORR: 30% #AACR25 nejm.org/doi/full/10.10…

T-DXd vs. Zongertinib in HER2-Mutant NSCLC: Or Sequential Use? Efficacy: Zongertinib➡️71% ORR, 14.1-mo response duration, 12.4-mo PFS. 48% ORR post-T-DXd! T-DXd➡️55% ORR, 9.3-mo response, 8.2-mo PFS, 17.8-mo OS. 💥Zongertinib has higher ORR/PFS; T-DXd provides OS data.

D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial G12Ci-naive ORR NSCLC➡️67% CRC➡️89% Pancreatic➡️75% G12Ci-pretreated ORR NSCLC➡️30% No G4 or 5 TRAE 💥The new generation KRAS inhibitors seem quite effective nature.com/articles/s4159…

Highlights from the 2025 Cancer Statistics Report: Cancer Deaths: From 1991 to 2022, mortality dropped 34%, preventing 4.5M deaths due to less smoking, early detection, and better treatments. New Cases: 2,041,910 new cases expected in 2025 (~5600/day). Men: 1,053,250; women:

Real-world comparison of pembro alone and combined with chemo in metastatic lung adenocarcinoma patients with PD-L1 ≥50% mOS➡️22.6 vs. 14.2 mo 💥Comparable or superior survival with combination therapy in most subgroups 💥Notable benefits in females, stage IVB disease, and

⏰️Less Than 2 Weeks to ESMO Breast Cancer 2025! Some studies to be presented👇 LBA1 - Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years'

GASTRIC CANCER thelancet.com/journals/lance…

The most effective medicine is the one you can access...

My Top 10 Breast Cancer Abstracts list at #ASCO25 👇

Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the EORTC 💥Pragmatic clinical trials in cancer research offer real-world results that better align with everyday patient care! thelancet.com/journals/lanon…

Global, Regional, and National Burden of Breast Cancer, 1990–2021, and Projections to 2050 2021 Snapshot➡️2.12M new cases (incidence rate: 24.56/100,000, age-adjusted), 674K deaths (mortality rate: 7.90/100,000, age-adjusted), 2.06M DALYs (healthy years lost) Trends➡️ Incidence

One page takeaway from #NIAGARA study that resulted in #durvalumab’s FDA Oncology approval on March 28, 2025 for resectable muscle invasive #BladderCancer #OncTwitter #MedTwitter #gusm OncoAlert Tom Powles

📣It was announced that the DESTINY-Breast11 study yielded positive results in terms of pCR. The comparison arms referenced in the pCR announcement are: T-DXd ➡️ THP vs ddAC ➡️ THP astrazeneca.com/media-centre/p…

Even though the result is positive, I couldn’t get too excited about this news due to the comparison arms. The monotherapy arm was closed after the interim evaluation??? Since we’re afraid of the toxicity of anthracyclines, we avoid anthracycline-based regimens as much as

#ESMOBreast25 is in 5 Days! One of the key upcoming presentations: EMBER-3 Subgroup Analysis 📌Imlunestrant + abema improved PFS after CDK4/6i (vs. Imlu) 📌No abema benefit after abema 📌Efficacy observed after palbo and ribo 💥Consistent benefit in ESR1+ and PI3K-mutant